

B. In the Claims:

Please cancel claims 1 to 11 without prejudice, and add the following new claims.

Upon entry of the present amendment, the status of the claims will be as follows:

1 to 11. (Cancelled)

12. (New) A method of ameliorating cellular accumulation or an inflammatory disorder having a pathogenesis associated with cells having a defective apoptosis gene or expressing a defective apoptosis polypeptide in a subject, comprising contacting the cells with an agent that kills cells having a defective apoptosis gene or expressing a defective apoptosis polypeptide, thereby ameliorating the cellular accumulation or inflammatory disorder.

13. (New) The method of claim 12, wherein contacting the cells with the agent comprises targeting the defective apoptosis gene or polypeptide.

14. (New) The method of claim 12, wherein the agent modulates a defective or aberrant apoptosis pathway in the cells.

15. (New) The method of claim 12, wherein the agent alters the activity of an apoptosis gene or apoptosis polypeptide.

16. (New) The method of claim 12, wherein the agent comprises a peptide or a peptide analog.

17. (New) The method of claim 16, wherein the peptide comprises an apoptotic polypeptide, or a fragment of an apoptotic polypeptide having apoptotic activity.

18. (New) The method of claim 16, wherein the apoptotic polypeptide comprises p53, bax, ICE, ras, or p21waf.

19. (New) The method of claim 16, wherein the peptide binds to the cells having a defective apoptosis gene or expressing a defective apoptosis polypeptide.

20. (New) The method of claim 16, wherein the peptide comprises an antibody, or an antigen binding fragment of an antibody.

21. (New) The method of claim 20, wherein the antigen binding fragment of an antibody is an Fab' fragment, an (Fab')2 fragment, or an Fv fragment.

22. (New) The method of claim 20, wherein the antibody selectively binds fas.

23. (New) The method of claim 12, wherein the agent further comprises a toxin or a peptide, which is conjugated to the agent.

24. (New) The method of claim 12, wherein the agent is a peptidomimetic.

25. (New) The method of claim 12, further comprising, prior to contacting the cells with the agent that kills cells having a defective apoptosis gene or expressing a defective apoptosis polypeptide, administering to the subject an agent that protects cells having a wild-type apoptosis gene or expressing a wild-type apoptotic polypeptide from the agent that kills cells having the defective apoptosis gene or expressing the defective apoptosis polypeptide.

26. (New) A method of ameliorating cellular accumulation or an inflammatory disorder having a pathogenesis associated with cells having a defective apoptosis gene or expressing a defective apoptosis polypeptide in a subject, comprising contacting the cells with an agent that enhances apoptosis of the cells, thereby ameliorating the cellular accumulation or inflammatory disorder.

In the Application of:
Firestein et al.
U.S. Serial No. Not yet assigned
Filed: Herewith
Continuation of U.S. Serial No.: 09/363,997
Page 5

PATENT
Attorney Docket No.: UCSD1160-4

27. (New) The method of claim 26, wherein contacting the cells with the agent comprises targeting the defective apoptosis gene or polypeptide.
28. (New) The method of claim 26, wherein the agent comprises a peptide.
29. (New) The method of claim 28, wherein the peptide comprises an apoptotic polypeptide.
30. (New) The method of claim 29, wherein the apoptotic polypeptide comprises p53, bax, ICE, ras, or p21waf.
31. (New) The method of claim 28, wherein the peptide comprises an antibody, or an antigen binding fragment of an antibody.